Grifols, S.A. (GIKLY)

Market Cap	6.20B -4.2%
Revenue (ttm)	8.83B +4.3%
Net Income	472.00M +156.1%
EPS	0.69 +156.5%
Shares Out	n/a
PE Ratio	13.13
Forward PE	8.62
Dividend	0.07 (1.37%)
Ex-Dividend Date	Aug 12, 2025

Volume	434
Average Volume	852
Open	5.18
Previous Close	n/a
Day's Range	5.18 - 5.18
52-Week Range	4.23 - 7.49
Beta	1.19
RSI	41.83
Earnings Date	May 5, 2026

About Grifols

Grifols, S.A., together with its subsidiaries, engages in the research, development, production, and marketing of plasma-derived medicines in the United States, Canada, Spain, Europe, and internationally. It operates through four segments: Biopharma, Diagnostic, Bio Supplies, and Others. The company offers various hemoderivatives from human plasma for immunology, infectious diseases, hepatology, intensive care, pulmonology, hematology, and neurology treatment areas; and markets diagnostic testing equipment, reagents, and other equipment, as wel...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 1909
• Employees: 25,258
• Stock Exchange: OTCMKTS
• Ticker Symbol: GIKLY

Financial Performance

In 2025, Grifols's revenue was 7.52 billion, an increase of 4.33% compared to the previous year's 7.21 billion. Earnings were 402.00 million, an increase of 156.05%.

Financial numbers in EUR